[PDF] Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. | Semantic Scholar (2024)

Skip to search formSkip to main contentSkip to account menu

Semantic ScholarSemantic Scholar's Logo
@article{Jones2005EvaluationOP, title={Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.}, author={Ronald N. Jones and Thomas R. Fritsche and Yigong Ge and Kon{\'e} Kaniga and Helio Silva Sader}, journal={The Journal of antimicrobial chemotherapy}, year={2005}, volume={56 6}, pages={ 1047-52 }, url={https://api.semanticscholar.org/CorpusID:30847990}}
  • Ronald N. Jones, T. Fritsche, H. Sader
  • Published in Journal of Antimicrobial… 1 December 2005
  • Medicine

PI-0903M was generally bactericidal against tested species, and the MIC results were stable across numerous susceptibility test condition changes, as well as in vitro testing parameters for this compound.

38 Citations

Background Citations


Results Citations


Figures and Tables from this paper

  • table 1
  • figure 1
  • table 2
  • table 2
  • table 3
  • table 4

38 Citations

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
    Ronald N. JonesD. FarrellR. MendesH. Sader


    The Journal of antimicrobial chemotherapy

  • 2011

Ceftaroline exhibited promising high potency and wide coverage against Gram-positive and -negative pathogens known to cause CAP, especially isolates of MDR pneumococci and methicillin-resistant S. aureus.

  • 65
  • PDF
In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.
  • 20
In vitro activity of ceftaroline and other antimicrobial agents against Gram positive bacterial isolates: Descriptive study from a university hospital.
    Tasneem SiddiquiC. SahuS. Patel


    Indian journal of medical microbiology

  • 2021
  • 1
  • PDF
In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
    C. VidaillacSteven N. LeonardH. SaderRonald N. JonesM. Rybak


    Antimicrobial Agents and Chemotherapy

  • 2009

Cefaroline plus amikacin appeared as the most likely synergistic combination against resistant gram-negative pathogens and represents a promising therapeutic option, and further studies are warranted to elucidate the clinical value of ceftaroline combinations againstresistant gram- negative pathogens.

  • 60
  • PDF
Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    H. PoonMei‐Hwei ChangH. B. Fung


    Clinical therapeutics

  • 2012
  • 45
Pharmacodynamics of Ceftaroline against Staphylococcus aureus Studied in an In Vitro Pharmaco*kinetic Model of Infection
    A. MacgowanA. NoelS. TomaselliK. Bowker


    Antimicrobial Agents and Chemotherapy

  • 2013

Data support the use of ceftaroline fosamil at doses of 600 mg q12h to treat S. aureus strains with MICs of ≤2 μg/ml, and an fTMIC of 25 to 30% would make a suitable pharmacodynamic index target, but f TMIC values of ≥50% are needed to suppress the emergence of resistance and require clinical evaluation.

  • 51
  • PDF
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    D. FarrellM. CastanheiraR. MendesH. SaderRonald N. Jones


    Clinical infectious diseases : an official…

  • 2012

Ceftaroline surveillance in the United States during 2008-2010 documented sustained potency and spectrum against multidrug-resistant S. aureus and multidrog- resistant S. pneumoniae known to cause ABSSSI and CABP.

  • 86
  • PDF
Ceftaroline Fosamil: A Novel Broad-Spectrum Cephalosporin with Activity Against Methicillin-Resistant Staphylococcus aureus
    M. JorgensonD. DepestelP. Carver


    The Annals of pharmacotherapy

  • 2011

Ceftaroline has excellent in vitro activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), which makes it an attractive monotherapy, but it lacks activity against problem gram-negative bacteria (eg, Pseudomonas spp.), which will likely limit its use for serious health care-associated infections.

  • 30
Assessment of CEM-101 Susceptibility Testing Conditions and Optimization of Disk Diffusion Methods
    Ronald N. Jones


  • 2008

CLSI broth microdilution was used and test conditions were modified to determine effects of CEM-101 activity and simultaneous changes in the pH and protein were tested.

  • PDF
In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC Testing
    Steven D. BrownM. Traczewski


    Antimicrobial Agents and Chemotherapy

  • 2008

The spectrum of activity of ceftaroline was evaluated against 1,247 bacterial isolates representing 44 different species or phenotypic groups and for the majority of species, the activity was comparable or superior to that of Ceftriaxone.

  • 46
  • PDF



12 References

In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci
    T. FujimuraY. YamanoI. YoshidaJ. ShimadaS. Kuwahara


    Antimicrobial Agents and Chemotherapy

  • 2003

S-3578 exhibited a broad antibacterial spectrum and, particularly, had excellent activity against gram-positive bacteria including methicillin-resistant staphylococci and PRSP, which was comparable to that of ceftriaxone.

  • 33
  • PDF
Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
    H. SaderT. FritscheK. KanigaYigong GeRonald N. Jones


    Antimicrobial Agents and Chemotherapy

  • 2005

PI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against Gram-negative pathogens.

  • 153
  • PDF
In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci
    H. SaderDavid M. JohnsonRonald N. Jones


    Antimicrobial Agents and Chemotherapy

  • 2004

The novel cephalosporin was 8- to 16-fold more potent than ceftriaxone, cefepime, or amoxicillin-clavulanate against both penicillin-intermediate and -resistant S. pneumoniae and was highly active against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci.

  • 58
  • PDF
In Vitro Activities of RWJ-54428 (MC-02,479) against Multiresistant Gram-Positive Bacteria
    S. ChamberlandJohanne Blais M. Dudley


    Antimicrobial Agents and Chemotherapy

  • 2001

This survey of the susceptibilities of more than 1,000 multidrug-resistant gram- positive isolates to RWJ-54428 indicates that this new cephalosporin has the potential to be useful in the treatment of infections due to gram-positive bacteria, including strains resistant to currently available antimicrobials.

  • 38
  • PDF
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
    Ronald N. JonesL. DeshpandeA. MutnickD. Biedenbach


    The Journal of antimicrobial chemotherapy

  • 2002

BAL9141 demonstrated excellent activity against many tested pathogens displaying various resistance phenotypes, and should be particularly valuable in the treatment of MRSA as well as for drug-resistant streptococci, while maintaining a spectrum resembling a 'third-generation' cephalosporin against other clinically important species.

  • 127
  • PDF
In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599
    Y. IizawaJunko Nagai K. Okonogi

    Chemistry, Medicine

    Journal of infection and chemotherapy : official…

  • 2004

The usefulness of TAK-599 in the treatment of MRSA infections in humans is suggested, as it showed more rapid and distinct decrease of viable cells of two MRSA strains than did vancomycin and linezolid in vitro.

  • 88
TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.
    T. IshikawaN. Matsunaga A. Miyake

    Chemistry, Medicine

  • 2003
  • 123
Clinical Microbiology Procedures Handbook
    H. Isenberg


  • 2004

This well-respected reference continues to serve as the sole major publication providing step-by-step descriptions that enable clinical microbiologists and their staffs to perform all analyses and their control from the receipt of the specimen to the final report.

  • 1,158
National Committee for Clinical Laboratory Standards.
    E. Bruck



  • 1980

Many members of the Academy of Pediatrics seem to be generally unaware of the fact that your Academy has participated for ten years in a very interesting and valuable organization, the National

  • 12,844



Related Papers

Showing 1 through 3 of 0 Related Papers

    [PDF] Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. | Semantic Scholar (2024)


    What is the new cephalosporin for MRSA? ›

    Ceftaroline is a novel fifth-generation cephalosporin, which exhibits broad-spectrum activity against Gram-positive bacteria, including MRSA and extensively-resistant strains, such as vancomycin-intermediate S. aureus (VISA), heteroresistant VISA (hVISA), and vancomycin-resistant S. aureus (VRSA).

    Does Ceftaroline cover Pseudomonas? ›

    Ceftaroline demonstrated less potent activity (MIC90, ≥4 μg/ml) against Enterobacter spp., Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella oxytoca, Serratia marcescens, and Stenotrophom*onas maltophilia.

    What is the strongest antibiotic for staph infection? ›

    Antibiotics commonly prescribed to treat staph infections include cefazolin, nafcillin, oxacillin, vancomycin, daptomycin and linezolid. For serious staph infections, vancomycin may be required. This is because so many strains of staph bacteria have become resistant to other traditional antibiotics.

    What kind of antibiotic is cephalosporin? ›

    Cephalosporins are β-lactam antimicrobials used to manage various infections caused by both gram-positive and gram-negative bacteria. The 5 generations of cephalosporins demonstrate efficacy in treating skin and soft tissue infections, pneumonia, meningitis, and other infections.

    What antibiotic does not cover Pseudomonas? ›

    Of these, only imipenem, meropenem and doripenem are active against Pseudomonas aeruginosa. Ertapenem has no activity against this organism.

    Which antibiotic is active against Pseudomonas? ›

    Pseudomonas infection can be treated with a combination of an antipseudomonal beta-lactam (eg, penicillin or cephalosporin) and an aminoglycoside. Carbapenems (eg, imipenem, meropenem) with antipseudomonal quinolones may be used in conjunction with an aminoglycoside.

    What is the best antibiotic to use when treating a gram-positive bacterial disease? ›

    Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.

    What is the newest antibiotic for MRSA? ›

    The recently launched drug linezolid helps to treat MRSA infections and other drug-resistant bacterial infections. Linezolid has a wide range of activity against MRSA, methicillin-resistant S. epidermidis (MRSE), vancomycin-resistant S.

    What is the last resort antibiotic for MRSA? ›

    Carbapenems (such as imipenem/cilastatin) — used as a drug of last resort for a variety of different bacterial infections. Ceftobiprole and ceftaroline — fifth-generation cephalosporins active against methicillin-resistant Staphylococcus aureus (MRSA); use is limited to prevent development of drug resistance.

    What is the best antibiotic combination for MRSA? ›

    Vancomycin or daptomycin are the agents of choice for treatment of invasive MRSA infections [1]. Alternative agents that may be used for second-line or salvage therapy include telavancin, ceftaroline, and linezolid.

    What is the latest cephalosporin? ›

    Cefiderocol is the latest novel 5th–6th generation cephalosporin to be approved by the FDA in November 2019 for the treatment of complicated urinary tract infections (UTIs) and pyelonephritis, and in September 2020 it was approved for hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP).

    Top Articles
    Latest Posts
    Article information

    Author: Gregorio Kreiger

    Last Updated:

    Views: 5699

    Rating: 4.7 / 5 (77 voted)

    Reviews: 92% of readers found this page helpful

    Author information

    Name: Gregorio Kreiger

    Birthday: 1994-12-18

    Address: 89212 Tracey Ramp, Sunside, MT 08453-0951

    Phone: +9014805370218

    Job: Customer Designer

    Hobby: Mountain biking, Orienteering, Hiking, Sewing, Backpacking, Mushroom hunting, Backpacking

    Introduction: My name is Gregorio Kreiger, I am a tender, brainy, enthusiastic, combative, agreeable, gentle, gentle person who loves writing and wants to share my knowledge and understanding with you.